Market revenue in 2023 | USD 987.0 million |
Market revenue in 2030 | USD 2,442.8 million |
Growth rate | 13.8% (CAGR from 2023 to 2030) |
Largest segment | Reagents & kits |
Fastest growing segment | Reagents & kits |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Instruments, Reagents & kits, Services |
Key market players worldwide | Illumina Inc, Thermo Fisher Scientific Inc, Qiagen NV, Roche, Fluidigm Corporation, Danaher Corp, Agilent Technologies, Eurofins Scientific SE, GE HealthCare Technologies Inc Common Stock, Bio-Rad Laboratories Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to genotyping market will help companies and investors design strategic landscapes.
Reagents & kits was the largest segment with a revenue share of 61.09% in 2023. Horizon Databook has segmented the Germany genotyping market based on instruments, reagents & kits, services covering the revenue growth of each sub-segment from 2018 to 2030.
The genotyping market in Germany is driven by increasing prevalence of chronic diseases and genetic diseases. In addition, healthcare expenditure in Germany is considered to be the highest in Europe. It was USD 5,472 in 2018, accounting for an increase of 8.3% from 2017. Hence, high healthcare expenditure and improvements in healthcare infrastructure are among factors driving the market.
Key manufacturers, such as Roche and Bio-Rad, are strengthening their operations in Germany. In addition, presence of dedicated genotyping companies, such as IKMB Genotyping, in this region is expected to boost genotyping market.
Rise in the number of collaborations between government and nongovernment organizations is anticipated to drive market growth. For instance, the German Federal Ministry of Education and Research granted EUR 3 million to research personalized medicine to treat glioblastoma.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany genotyping market , including forecasts for subscribers. This country databook contains high-level insights into Germany genotyping market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account